BCAX

Bicara Therapeutics Inc. Common Stock
BCAX
Market cap $1.37B

25.16 USD

+1.36

5.71%

At close Oct 4, 4:00 PM EDT

1 day

5.71%

5 days

-1.10%

1 month

-0.98%

3 months

-0.98%

6 months

-0.98%

Year to date

-0.98%

1 year

-0.98%

5 years

-0.98%

About: Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.

–

Funds holding %

of 6,728 funds

–

Analysts bullish %

Fund manager confidence

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for BCAX.

See Analyst Rankings

Financial journalist opinion

Based on 8 articles about BCAX published over the past 30 days

24/7 Wall Street

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying

24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.

Last Week's 3 Biotech IPOs Prompt Huge Insider Buying

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Bicara Therapeutics' shares began trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” All of the shares of common stock were sold by Bicara Therapeutics.

Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.

U.S. IPO Weekly Recap: 3 Biotechs Lead Active September IPO Market

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Shares of Bicara Therapeutics surged nearly 46% in their market debut on Friday, signaling strong investor interest for the TPG-backed cancer therapy developer.

TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

BOSTON, Sept. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the pricing of its initial public offering of 17,500,000 shares of its common stock at a public offering price of $18.00 per share. Bicara Therapeutics' shares are expected to begin trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” The offering is expected to close on September 16, 2024, subject to the satisfaction of customary closing conditions. In addition, Bicara Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 2,625,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the shares of common stock are being offered by Bicara Therapeutics.

Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

Bicara Therapeutics, a TPG-backed biopharmaceutical company developing a therapy targeting tumors, said on Wednesday it plans to raise up to $265 million through an upsized initial public offering (IPO) in the United States.

Bicara Therapeutics targets $265 mln proceeds in upsized US IPO

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. Eight IPOs submitted initial filings this past week, including three names that filed to raise $100 million or more. Two biotechs are scheduled to complete IPOs next Thursday, each aiming to raise $200 million.

U.S. IPO Weekly Recap: 2 APAC Microcaps Go Public In Short Labor Day Week As The Pipeline Grows

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Bicara Therapeutics said on Friday it is seeking a valuation of up to $828 million in its initial public offering in the United States, as new listings continue to flock the markets.

Bicara Therapeutics aims for up to $828 mln valuation in U.S. IPO

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

Bicara Therapeutics aims to raise $200 million through an IPO to advance its promising bifunctional antibody treatment for head and neck cancers. The primary drug candidate, ficerafusp alfa, has shown a 54% response rate in Phase 1/1b trials and will enter Phase 2/3 trials soon. The global head and neck cancer therapeutics market is expected to grow significantly, reaching $4.4 billion by 2030, driven by increasing cancer incidence.

Bicara Therapeutics Plans $200 Million IPO For Head & Neck Cancer Drug

See News Rankings

Charts implemented using Lightweight Charts™